1. Home
  2. HCAT vs MDWD Comparison

HCAT vs MDWD Comparison

Compare HCAT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCAT
  • MDWD
  • Stock Information
  • Founded
  • HCAT 2008
  • MDWD 2000
  • Country
  • HCAT United States
  • MDWD Israel
  • Employees
  • HCAT N/A
  • MDWD N/A
  • Industry
  • HCAT Computer Software: Programming Data Processing
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • HCAT Technology
  • MDWD Health Care
  • Exchange
  • HCAT Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • HCAT 259.8M
  • MDWD 230.6M
  • IPO Year
  • HCAT 2019
  • MDWD 2014
  • Fundamental
  • Price
  • HCAT $4.10
  • MDWD $19.29
  • Analyst Decision
  • HCAT Buy
  • MDWD Strong Buy
  • Analyst Count
  • HCAT 11
  • MDWD 2
  • Target Price
  • HCAT $8.00
  • MDWD $35.00
  • AVG Volume (30 Days)
  • HCAT 672.5K
  • MDWD 55.3K
  • Earning Date
  • HCAT 08-06-2025
  • MDWD 08-13-2025
  • Dividend Yield
  • HCAT N/A
  • MDWD N/A
  • EPS Growth
  • HCAT N/A
  • MDWD N/A
  • EPS
  • HCAT N/A
  • MDWD N/A
  • Revenue
  • HCAT $311,274,000.00
  • MDWD $19,213,000.00
  • Revenue This Year
  • HCAT $11.23
  • MDWD $20.80
  • Revenue Next Year
  • HCAT $9.71
  • MDWD $26.92
  • P/E Ratio
  • HCAT N/A
  • MDWD N/A
  • Revenue Growth
  • HCAT 4.88
  • MDWD N/A
  • 52 Week Low
  • HCAT $3.49
  • MDWD $14.14
  • 52 Week High
  • HCAT $9.24
  • MDWD $24.00
  • Technical
  • Relative Strength Index (RSI)
  • HCAT 48.15
  • MDWD 43.03
  • Support Level
  • HCAT $3.65
  • MDWD $19.11
  • Resistance Level
  • HCAT $3.93
  • MDWD $19.87
  • Average True Range (ATR)
  • HCAT 0.22
  • MDWD 0.57
  • MACD
  • HCAT 0.00
  • MDWD -0.21
  • Stochastic Oscillator
  • HCAT 40.91
  • MDWD 27.77

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: